<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04209166</url>
  </required_header>
  <id_info>
    <org_study_id>CRC2018ZD05</org_study_id>
    <nct_id>NCT04209166</nct_id>
  </id_info>
  <brief_title>A Study of Individualized Diagnosis and Treatment for Major Depressive Disorder With Atypical Features</brief_title>
  <official_title>A Study of Individualized Diagnosis and Treatment for Major Depressive Disorder With Atypical Features</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fourth Military Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangzhou Psychiatric Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dalian Seventh People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Mental Health Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The lifetime prevalence of major depressive disorder (MDD) is 10%~20%. Worldwide, nearly 340
      million individuals have suffered the torture of depression. World Health Organization has
      reported that MDD would become the most serious global burden of disease and eventually turn
      into a public health problem in 2030. Varied clinical symptoms, inappropriate treatment,
      unclear pathogenesis, and lack of recurrent risk early-warning predictors cause a series of
      clinical problems, such as low diagnostic rate, low effective treatment rate, and high
      recurrent rate. Hence, this study aims to search multidimensional markers for early diagnosis
      of MDD, to establish optimized personalized therapy, and to explore sensitive recurrence
      predictors.

      Based on the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth
      Edition (DSM-5), MDD is subdivided into eight different clinical specifiers, one of which the
      incident rate of MDD with atypical features reaches 30%~38%. However, there is still a lack
      of meta-evidence for the clinical treatment strategy in MDD with atypical features. And 45.4
      percentage of MDD with atypical features convert to bipolar disorder. Therefore, this study
      will focus on three issues about what's the objective endophenotype in MDD with atypical
      features, how to select appropriate personalized treatment for MDD with atypical features,
      what's the predictive biomarker of conversion to bipolar disorder.

      Based on the investigators' previous findings, this study will investigate adult depression
      at a cross-sectional study and a prospective cohort study. Multivariate informatics analysis
      was performed from three research dimensions (cognitive neuropsychology, metabonomics, and
      multimodal neuroimaging), including atypical features, &quot;cold/hot&quot; cognition assessment, KP
      (kynurenine pathway) metabolomics and inflammatory factors, multimodal MRI robust property.
      Referring guidelines for the diagnosis and treatment of depression and evidence-based
      medicine evidence, MDD with atypical features are divided into f groups (antidepressants,
      antidepressants+mood stabilizers, mood stabilizers, treat as usual). Then, the investigators
      perform follow-up to verify optimized treatment strategies and to explore risk factors of
      conversion from MDD with atypical features to bipolar disorder. Furthermore, this study
      performs correlation analysis to analyze cross-omics data, weight coefficient analysis to
      analyze multidimensional indexes, clustering analysis to analyze multivariate bio-information
      data, and artificial intelligence technologies (such as pattern recognition, and machine
      learning) to realize the transformation from medical data to practical transformation.
      Eventually, this study builds three specific models (the multidimensional early diagnosis
      models for MDD with atypical features, the optimized personalized therapy model, and the
      recurrence and conversion risk early-warning model), which form the integrated intelligent
      platform for multidimensional diagnosis, personalized treatment, recovery management of MDD
      with atypical features.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 12, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>remission of acute phase</measure>
    <time_frame>12th week</time_frame>
    <description>scored 7 or lower on the Hamilton's Depression Scale with 24 items</description>
  </primary_outcome>
  <primary_outcome>
    <measure>switch rate</measure>
    <time_frame>4th year</time_frame>
    <description>the rate of patients who switch from depression to mania or hypomania during 4-year follow-up</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">780</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>FAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the first-episode major depressive disorder with atypical feature</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the recurrent major depressive disorder with atypical feature who have been medication-free for no less than 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BD</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>the depressive episode of bipolar disorder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HC</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>healthy control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)</intervention_name>
    <description>Patients will be treated with Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors.</description>
    <arm_group_label>FAD</arm_group_label>
    <arm_group_label>RAD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SSRIs/SNRIs+Mood Stabilizer</intervention_name>
    <description>Patients will be treated with Mood Stabilizer combined with Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors.</description>
    <arm_group_label>FAD</arm_group_label>
    <arm_group_label>RAD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SSRIs/SNRIs+Quetiapine</intervention_name>
    <description>Patients will be treated with Quetiapine combined with Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors.</description>
    <arm_group_label>FAD</arm_group_label>
    <arm_group_label>RAD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Usual Treatment</intervention_name>
    <description>Patients' treatment will be decided by the clinical doctor.</description>
    <arm_group_label>FAD</arm_group_label>
    <arm_group_label>RAD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 16-60 years old;

          2. Meeting with the criteria of major depressive disorder in the Diagnostic and
             Statistical Manual of Mental Disorders (DSM)-5;

          3. Scored 20 or higher on the Hamilton's Depression Scale with 24 items (HAMD-24);

          4. With enough audio-visual ability and comprehensive ability to accomplish the visits;

          5. Be necessary and suitable to accept the treatment of antidepressants;

          6. Scored less than 14 on Hamilton's Anxiety Scale (HAMA) and scored less than 14 on the
             Hypomania Symptom Checklist-32 (HCL-32);

          7. With 2 or more atypical symptoms including significant weight gain or increase in
             appetite, hypersomnia, leaden paralysis, and a long-standing pattern of interpersonal
             rejection sensitivity that results in significant social or occupational impairment.

        Exclusion Criteria:

          1. Severe medical or neurological problems;

          2. Previous mania or hypomania episodes;

          3. Female patients who are pregnant, planning to be pregnant or breastfeeding;

          4. Actively suicide ascertained by research psychiatrist or 3rd item of HAMD
             scoredâ‰¥3(suicidality);

          5. Had ECT, MECT or rTMS in the past 6 months;

          6. Experienced severe personality disorder, mental retardation, anorexia/bulimia nervosa.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daihui Peng, MD. PhD.</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai Mental Health Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daihui Peng, MD. PhD.</last_name>
    <phone>18017311136</phone>
    <email>pdhsh@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guangzhou Psychiatric Hospital</name>
      <address>
        <city>Guanzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guiyun Xu, MD</last_name>
      <phone>18922165291</phone>
      <email>13650774898@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuhan Mental Health Center</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yi Li, MD</last_name>
      <phone>13554013182</phone>
      <email>psylee@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dalian Seventh People's Hospital</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <zip>116000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shoufu Xie, MD</last_name>
      <phone>13998622066</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Mental Health Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daihui Peng, M.D.,Ph.D.</last_name>
      <phone>18017311136</phone>
      <email>pdhsh@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fourth Military Medical University</name>
      <address>
        <city>Xian</city>
        <state>Shanxi</state>
        <zip>710000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Huaning Wang, MD</last_name>
      <phone>13609161341</phone>
      <email>13609161341@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>December 16, 2019</study_first_submitted>
  <study_first_submitted_qc>December 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2019</study_first_posted>
  <last_update_submitted>December 20, 2019</last_update_submitted>
  <last_update_submitted_qc>December 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Norepinephrine</mesh_term>
    <mesh_term>Quetiapine Fumarate</mesh_term>
    <mesh_term>Serotonin</mesh_term>
    <mesh_term>Serotonin Uptake Inhibitors</mesh_term>
    <mesh_term>Serotonin and Noradrenaline Reuptake Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

